PTPRC and hematopoietic and lymphoid system neoplasm: Lastly, since the CD45 antigen is expressed by all nucleated cells of hematopoietic origin (including their malignant counterparts), Wellhausen and colleagues envisioned the use of CD45-epitope editing of HSCs to develop a universal CAR-T cell therapy for blood cancers with no off-tumor toxicities (103).